User profiles for T. E. King
Talmadge E. King, JrProfessor & Dean, School of Medicine, University of California San Francisco Verified email at ucsf.edu Cited by 75161 |
Idiopathic pulmonary fibrosis
… Prof Talmadge E King Jr, MD Talmadge E King Jr … Correspondence to: Prof Talmadge E
King Jr, Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue…
King Jr, Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue…
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy
Idiopathic pulmonary fibrosis is a progressive and usually fatal lung disease characterized
by fibroblast proliferation and extracellular matrix remodeling, which result in irreversible …
by fibroblast proliferation and extracellular matrix remodeling, which result in irreversible …
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
B Ley, HR Collard, TE King Jr - American journal of respiratory and …, 2011 - atsjournals.org
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some …
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some …
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
…, DM Hansell, T Johkoh, DS Kim, TE King Jr… - American journal of …, 2011 - atsjournals.org
This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …
[HTML][HTML] A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
TE King Jr, WZ Bradford… - New England journal …, 2014 - Mass Medical Soc
Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …
An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial …
… Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE Jr.
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective …
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective …
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable
loss of lung function. The CAPACITY programme (studies 004 and 006) was designed …
loss of lung function. The CAPACITY programme (studies 004 and 006) was designed …
Acute exacerbations of idiopathic pulmonary fibrosis
…, KK Brown, RJ Kaner, TE King Jr… - American journal of …, 2007 - atsjournals.org
The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady,
predictable decline in lung function over time. Recent evidence suggests that some …
predictable decline in lung function over time. Recent evidence suggests that some …
A multidimensional index and staging system for idiopathic pulmonary fibrosis
…, BM Elicker, KD Jones, TE King Jr… - Annals of internal …, 2012 - acpjournals.org
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an
overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication…
overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication…
[BOOK][B] Murray and Nadel's textbook of respiratory medicine E-book: 2-volume set
RJ Mason, VC Broaddus, TR Martin, TE King… - 2010 - books.google.com
Murray and Nadel’s Textbook of Respiratory Medicine has long been the definitive and
comprehensive pulmonary disease reference. Robert J. Mason, MD now presents the fifth edition …
comprehensive pulmonary disease reference. Robert J. Mason, MD now presents the fifth edition …